Psilocybin reduces specific brain cells' activity while boosting others

Key Findings

🔬 Group psilocybin therapy helps cancer patients after initial partial response

• 13 cancer patients with metastatic disease received a second round of group retreat psilocybin therapy after partial response to initial treatment

• Depression scores dropped from 15.08 to 9.00 within 8 days and remained low at 24 weeks, with 69% achieving scores below clinical thresholds

• 77% experienced complete mystical experiences in the second session (up from 38% initially) using higher doses and optional boosters

💊 Ketamine shows faster antidepressant effects in bipolar vs unipolar depression

• 97 adults with treatment-resistant depression received intravenous ketamine in a naturalistic clinical setting

• Patients with bipolar depression showed faster and greater improvement than those with unipolar depression, with differences emerging at week 2 and lasting through 3 months

• Both groups experienced significant symptom reductions, but bipolar patients had superior and more sustained responses

🧬 New ketamine mechanism discovered through receptor cross-talk

• Ketamine's antidepressant action depends on interaction between TrkB and mGluR5 receptors in the brain

• mGluR5 amplifies brain-derived neurotrophic factor signaling while BDNF drives mGluR5 removal from synapses

• An mGluR5 enhancer can boost ketamine's effects, suggesting potential combination therapies

🎯 Ketamine's anti-suicide effects resist treatment resistance severity

• 154 adults with treatment-resistant depression received ketamine in controlled trials with symptom-specific analysis

• Anti-suicidal effects remained robust across all levels of treatment resistance

• Improvements in sadness and anxiety were diminished in patients with higher resistance scores

🧪 2C-B produces psychedelic effects similar to MDMA and psilocybin

• 24 healthy participants received 2C-B (10, 20, 30mg), MDMA (125mg), or psilocybin (25mg) in controlled trials

• 30mg 2C-B induced comparable drug effects to MDMA and increased emotional empathy similarly

• 2C-B had shorter duration (4.9 hours vs 6.1 for psilocybin) and caused less cardiovascular stimulation than MDMA

🔍 Magic mushrooms may have evolved to deter insects, not attract them

• Fruit fly larvae exposed to psilocybin-containing mushroom extracts showed reduced survival and pupation rates

• Adults exposed during development had smaller thorax and wing size with developmental stress indicators

• DNA analysis revealed distinct invertebrate communities around psilocybin mushrooms compared to non-psychedelic species